Quantcast

Industry news that matters to you.  Learn more

New Asthma Biomarkers Identified from Lung Bacteria

While the microbiome has gained significant attention for its impact on digestive health in recent years, its effect on lung disease has largely remained unstudied. Dr. Patricia Finn says this is a missed opportunity. “The microbiome is the ecosystem of good and bad bacteria living in the body,” said Finn, the Earl M. Bane Professor of Medicine at the University of Illinois at Chicago. “Because the lungs continuously and automatically draw air, and any number of environmental agents, into the body, the composition and balance of microbes in the lungs may have a profound effect on many respiratory conditions.” New research from Finn and her colleagues in the UIC College of Medicine suggests that the lung microbiome plays a significant role in asthma severity and response to treatment.

Are e-Cigarettes ‘Safer’ than Regular Cigarettes?

E-cigarettes appear to trigger unique immune responses as well as the same ones triggered by regular cigarettes, according to new research published online in the American Thoracic Society’s American Journal of Respiratory and Critical Care Medicine.

Big Pharma Joins NIH’s Cancer Moonshot for a Biomarker Hunt

Eleven drug companies are joining forces with the U.S. National Institutes of Health’s Cancer Moonshot to expedite the discovery of cancer immunotherapy biomarkers, molecular bar codes that help doctors know how to treat a tumor and gauge how well a person responds to a drug.

Quest Diagnostics’ Cleveland HeartLab Acquisition Reflects Personalized Medicine Trend

Quest Diagnostics has snapped up Cleveland Clinic spinoff Cleveland HeartLab in an equity deal and formed a strategic collaboration with the health system. The acquisition gives the national clinical lab testing business access to the HeartLab’s proprietary tests identifying biomarkers associated with cardiovascular disease that go well beyond the conventional screening tests for cholesterol.

Quest Diagnostics to Acquire Cleveland HeartLab and Form Strategic Collaboration with Cleveland Clinic

Quest Diagnostics (NYSE: DGX) today announced it has formed a definitive agreement to acquire Cleveland HeartLab, a leader in innovative diagnostic services for managing cardiovascular disease, from equity investors, including Cleveland Clinic. Quest intends to establish a national center of excellence in diagnostic information services at Cleveland HeartLab’s specialized laboratory in Cleveland, Ohio, focused on services that aid in assessing risk and treatment protocols for heart disease, the leading cause of death in the United States.